摘要
目前对帕金森病的药物治疗是相当不足的,近期需要改良的治疗剂。腺苷酸A2A受体和单胺氧化酶(MAO)B是抗帕金森病治疗性化合物设计的两个重要分子靶点。腺苷酸A2A受体拮抗剂是一类相对新的抗帕金森病制剂,通过多巴胺D2受体促进多巴胺介导的神经传递而起作用。MAO-B抑制剂已经被确定为帕金森病的治疗方法,并且可以抑制脑内MAO-B催化的多巴胺代谢物。这种保存减少了多巴胺的含量,并且扩展了多巴胺的作用。A2A拮抗剂和MAO-B抑制剂也与神经保护作用相关,进一步确定了帕金森病中这类化合物的作用。有趣的是,作为一种已知的腺苷受体拮抗剂咖啡因,近期被认为是A2A拮抗剂和MAO-B抑制剂设计与发现的先导化合物。这篇综述总结了发现咖啡因源MAO-B抑制剂近期所做的努力。前期对咖啡因源A2A拮抗剂的设计进行了广泛的综述。对在两个靶点作用的双靶点化合物的发现前景也进行了评估。阻断A2A受体和MAO-B激活和功能的化合物在治疗帕金森病患者方面也许起到协同作用。
关键词: 腺苷酸A2A 受体,咖啡因,药物设计,双靶向,抑制剂,单胺氧化酶,帕金森病
Current Medicinal Chemistry
Title:Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease
Volume: 22 Issue: 8
Author(s): Jacobus P. Petzer and Anel Petzer
Affiliation:
关键词: 腺苷酸A2A 受体,咖啡因,药物设计,双靶向,抑制剂,单胺氧化酶,帕金森病
摘要: The current pharmacological therapies for the treatment of Parkinson’s disease are mostly inadequate and recent, improved therapeutic agents are required. Two important molecular targets for the design of anti-parkinsonian therapeutic compounds are the adenosine A2A receptor and the enzyme, monoamine oxidase (MAO) B. Adenosine A2A receptor antagonists are a relatively new class of anti-parkinsonian agents, which act by potentiating dopamine-mediated neurotransmission via dopamine D2 receptors. MAO-B inhibitors are established therapy of Parkinson’s disease and inhibit the MAO-B-catalysed metabolism of dopamine in the brain. This conserves reduced dopamine stores and extends the action of dopamine. A2A antagonism and MAO-B inhibition have also been associated with neuroprotective effects, further establishing roles for these classes of compounds in Parkinson’s disease. Interestingly, caffeine, a known adenosine receptor antagonist, has been recently considered as a lead compound for the design and discovery of A2A antagonists and MAO-B inhibitors. This review summarizes the recent efforts to discover caffeinederived MAO-B inhibitors. The design of caffeine-derived A2A antagonists has been extensively reviewed previously. The prospect of discovering dual-target-directed compounds that act at both targets is also evaluated. Compounds that block the activation and function of both A2A receptors and MAO-B may have a synergistic effect in the treatment of patients with Parkinson’s disease.
Export Options
About this article
Cite this article as:
Jacobus P. Petzer and Anel Petzer , Caffeine as a Lead Compound for the Design of Therapeutic Agents for the Treatment of Parkinson’s Disease, Current Medicinal Chemistry 2015; 22 (8) . https://dx.doi.org/10.2174/0929867322666141215160015
DOI https://dx.doi.org/10.2174/0929867322666141215160015 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extracts of Bacopa monnieri (L) Pennell Down-Regulate the Expression of Leukotriene C<sub>4</sub> Synthase mRNA in HL-60 Cells and Suppress OVAInduced Inflammation in BALB/c Mice
Current Bioactive Compounds Non-Antidepressant Treatment of Generalized Anxiety Disorder
Current Clinical Pharmacology Age and Dose-Dependent Effects of Alpha-Lipoic Acid on Human Microtubule- Associated Protein Tau-Induced Endoplasmic Reticulum Unfolded Protein Response: Implications for Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Computational Studies on Isolated Compounds of Sclerochloa dura; their Efficacy towards Carbonic Anhydrase Inhibition and Anti-cancer Drug Targets
Letters in Drug Design & Discovery The Genetic Components of Alcohol and Nicotine Co-Addiction: From Genes to Behavior
Current Drug Abuse Reviews Flavonoids as Promising Lead Compounds in Type 2 Diabetes Mellitus: Molecules of Interest and Structure-Activity Relationship
Current Medicinal Chemistry SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Tandem Mass Spectrometry Newborn Screening for Inborn Errors of Intermediary Metabolism: Abnormal Profile Interpretation
Current Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Emerging Pharmacological Properties of Cholinergic Synaptic Transmission: Comparison between Mammalian and Insect Synaptic and Extrasynaptic Nicotinic Receptors
Current Neuropharmacology Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Cutting through the Complexities of mTOR for the Treatment of Stroke
Current Neurovascular Research Drug Repositioning: Antimalarial Activities of GABA Analogs in Mice Infected with <i>Plasmodium berghei</i>
Central Nervous System Agents in Medicinal Chemistry Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Current Medicinal Chemistry Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Current Medicinal Chemistry Blood-Brain Barrier ABC-transporter P-glycoprotein in Alzheimer's Disease: Still a Suspect?
Current Pharmaceutical Design Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Acne in the Adult
Mini-Reviews in Medicinal Chemistry